Portal Vein Flow Velocity as a Screening Tool for Oesophageal Varices in Cirrhotic Patients

NCT ID: NCT05228509

Last Updated: 2024-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-04

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Portal vein flow velocity as screening tool for prediction of oesophageal varices in cirrhotic patient without upper endoscopy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Portal vein flow velocity as screening tool for prediction of oesophageal varices in cirrhotic patient without upper endoscopy with its high cost \& complications Using portal vein flow velocity and the relation between it \& presence of oesophageal varices in cirrhotic patient \& its efficacy as a primary tool for these cases

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis Portal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* cirrhotic patients with oesophageal varices
* cirrhotic patients without oesophageal varices

Exclusion Criteria

* Patients with hepato-cellular carcinomas \[HCCs\], portal vein thrombosis, hepatic encephalopathy.
* Patients with positive HCV antibody, but without liver cirrhosis diagnostic criteria
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peter atef

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter atef

Peter rizk

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter At Munir, Master

Role: PRINCIPAL_INVESTIGATOR

Assiut University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Egypt .assiut.manfalout

Asyut, Manfalout, Egypt

Site Status RECRUITING

43

Asyut, Manfalout, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peter At Rizk

Role: CONTACT

01553529181

Atef Mu Rizk

Role: CONTACT

01003938077

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Patef

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.